olmesartan medoxomil/amlodipine/hydrochlorothiazide / Generic mfg. - LARVOL DELTA

Drugs for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Cardiovascular • Hypertension

Olmesartan-associated Collagenous Gastrointestinal Disorders: Case Report and Review of the Literature (ACG 2022) - "Case Description/ A 73-year-old man, with a history of tribenzor use (olmesartan-amlodipine-hydrochlorothiazide, 40 mg once a day for 5-10 years) for complicated hypertension and gastroesophageal reflux disease, developed severe diarrhea and weight loss...Healthcare providers should suspect this entity even in patients who have been using ARBs for years. Figure: Figure 1: Endoscopic images of the edematous duodenum with scalloping and loss of folds (A) and corresponding histologic findings of subepithelial collagen and villous blunting of the epithelium on trichrome stain x 100 (B)."

Clinical • Review • Cardiovascular • Celiac Disease • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • ELANE

The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease (Ren Fail) - P=NA, N=90; PMID: 23413781; "Amlodipine/valsartan therapy plus hydration did not reduce the risk of CIN in...CKD Stage 2 patients....there was a decrease in...GFR using the Levey Modification of Diet in Renal Disease formula in the amlodipine/valsartan group and CIN occurred at a higher frequency in this group; ARBs and CCBs may be withheld before CAG in high-risk patients."

Clinical data • Renal Disease

Protective effects of Rho kinase inhibitor, fasudil, on rats with chronic kidney disease (Am J Physiol Renal Physiol) - PMID: 23552860; "...fasudil with OL reduces proteinuria by protecting podocyte integrity and alters the interstitial macrophage density/phenotype, thereby exerting renoprotective effects against CKD."

Preclinical • Renal Disease

Difference in the effects of switching from Candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: The COTO study (Drug Des Devel Ther) - P=NA, N=317; "Clinic and morning home BP and urinary albumin levels showed a significant decrease from baseline at 16 weeks after switching to olmesartan in both the CO and the TO group....In contrast, clinic BP, morning home BP, and urinary albumin were significantly increased again 16 weeks after switching back to candesartan or telmisartan..."

Retrospective data • Renal Disease

Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension) (Hypertens Res) - P3, N=563; ORIENT (NCT00141453); "In patients with diabetic nephropathy and hypertension, olmesartan significantly reduced proteinuria, independent of ACEI treatment and cardiovascular outcome but failed to show additional renal benefit compared with ACEI treatment alone. The cardiovascular benefit of dual treatment requires further evaluation."

P3 data • Renal Disease

Erratum to: Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension : A randomized, double-blind, parallel-group, mult (Clin Drug Investig) - P3, N=NA; Abstract not available.

P3 data • Renal Disease

The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies (Nefrologia) - P=NA, N=53; "Administering high doses of olmesartan in patients with non-diabetic proteinuric nephropathy results in significant reductions in proteinuria. This decrease was independent of blood pressure control and other confounding factors. RAS polymorphisms may modulate the antiproteinuric response to treatment with ARBs."

Clinical data • Diabetic Nephropathy • Renal Disease

Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension (Intern Med) - P=NA, N=10; After 6 months of olmesartan treatment blood pressure decreased significantly from 156/88 mmHg before starting olmesartan to 135/76 mmHg; In eight out of ten subjects peripheral insulin sensitivity improved; Fasting glucose levels & HbA1c levels also decreased significantly

Clinical data • Renal Disease

The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease (Hypertens Res) - P=NA, N=46; A/B ratios of urinary protein, albumin & type IV collagen excretion in the olmesartan add-on group were significantly lower than those in non-ARB group despite comparable A/B ratios for eGFR in two groups; These results indicate that in hypertensive pts with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition

Clinical data • Renal Disease

Effects of dual blockade of the renin angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the orient; A post HOC analysis (WCN 2013) - Abstract#SU203; Presentation time: Sunday, June 2, 2013 - 11:00 AM; P3, N=563; Sponsor: Daiichi Sankyo; NCT00141453; "Olmesartan decreased proteinuria and reduced declining rate of renal function compared with placebo in the absence of ACEI, but less in the presence of ACEI. Olmesartan was well tolerated. A higher incidence of hyperkalemia was seen in the Olmesartan/ACEI combination."

P3 data • Renal Disease